

1 Feb



ATTORNEY DOCKET NO. 21101.0031U3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Fleckenstein, <i>et al.</i>)	Art Unit: 1614
)	
Application No. 10/528,684)	Examiner: Weddington, K.E.
)	
Filing Date: May 9, 2005)	Confirmation No. 4643
)	
For: MODULATING VESICULAR)	
MONOAMINE TRANSPORTER TRAFFICKING)	
AND FUNCTION: A NOVEL APPROACH FOR)	
THE TREATMENT OF PARKINSON'S DISEASE))	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.




ATTORNEY DOCKET NO. 21101.0031U3
Application No. 10/528,684

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Janell T. Cleveland
Registration No. 53,848


NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Janell T. Cleveland

5/1/07
Date



INFORMATION DISCLOSURE STATEMENT LIST		Complete if Known					
		Application Number	10/528,684				
(Use as many sheets as necessary)		Filing Date	May 9, 2005				
		First Named Inventor	Annette E. Fleckenstein				
		Group Art Unit	1614				
		Examiner Name	Weddington, K.E.				
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
NON-PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	B1	Adams JD Jr, Chang ML, Klaidman L, "Parkinson's disease – redox mechanisms," <i>Curr. Med. Chem</i> , 8:809-814 (2001)					
	B2	Albers DS and Sonsalla PK, "Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents," <i>J Pharmacol Exp Ther</i> , 275:1104-1114 (1995)					
	B3	Augustine, G.J., Burns, M.E., DeBello, W.M., Hilfiker, S., Morgan, J.R., Schweizer, F.E., Tokumaru, H., Umayahara, K., "Proteins involved in synaptic vesicle trafficking," <i>J. Physiol</i> , 520:33-41 (1999)					
	B4	Beavo JA, Bechtel PJ, Krebs EG, "Activation of protein kinase by physiological concentrations of cyclic AMP," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 71:3580-3583 (1974)					
	B5	Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Holson RR, "Further studies of the role of hyperthermia in methamphetamine neurotoxicity," <i>J Pharmacol Exp Ther</i> , 268:1571-1580 (1994)					
	B6	Bowyer J, Tank A, Newport G, Slikker W, Ali S, Holson R, "The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum," <i>J. Pharmacol. Exp. Ther.</i> , 260:817-824 (1992)					
	B7	Brown JM, Hanson GR and Fleckenstein AE, "Regulation of the vesicular monoamine transporter-2: A Novel mechanism for cocaine and other psychostimulants," <i>J Pharmacol Exp Ther</i> , 296:762-767 (2001)					
	B8	Brown JM, Hanson GR and Fleckenstein AE, "Cocaine-Induced increases in vesicular dopamine uptake: role of dopamine receptors," <i>J. Pharmacol Exp Ther</i> , 298:1150-1153 (2001)					
	B9	Buening MK and Gibb JW, "Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity," <i>Eur J Pharmacol</i> , 26:30-34 (1974)					
	B10	Butcher SP, Liptrot J, Aburthnott GW, "Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis," <i>Neurosci. Lett.</i> , 122:245-248 (1991)					
	B11	Challman TD, Lipsky JJ, "Methylphenidate: its pharmacology and uses," <i>Mayo Clin. Proc.</i> , 75:711-721 (2000)					

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/528,684
		Filing Date	May 9, 2005
		First Named Inventor	Annette E. Fleckenstein
		Group Art Unit	1614
		Examiner Name	Weddington, K.E.

	B12	Chapin, D.S., Lookingland, K.J., Moore, K.E., "Effects of LC mobile phase composition on retention times for biogenic amines, and their precursors and metabolites," <i>Curr. Separations</i> , 7:68-70 (1986)
	B13	Cohen G, "Monoamine oxidase and oxidative stress at dopaminergic synapses," <i>J. Neural. Transm. Suppl.</i> , 32:229-238 (1990)
	B14	Cubells, J.F., Rayport, S., Rajendran, G., Sulzer, D, "Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress," <i>J. Neurosci.</i> , 14:2260-2271 (1994).
	B15	Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ and Marshall JF, "Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine," <i>Brain Res</i> , 598:321-326 (1992)
	B16	Erickson JD, Eiden LE, Hoffman BJ, "Expression cloning of a reserpine-sensitive vesicular monoamine transporter," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 89:10993-10997 (1992)
	B17	Fahn S, Cohen G, "The oxidant stress hypothesis in Parkinson's disease: evidence supporting it," <i>Ann. Neurol.</i> , 32:804-812 (1992)
	B18	Fleckenstein AE, Gibb JW and Hanson GR, "Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity," <i>Eur J Pharmacol.</i> , 406:1-13 (2000)
	B19	Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW and Hanson GR, "Rapid and reversible effects of methamphetamine on dopamine transporters," <i>J Pharmacol Exp Ther</i> , 282:834-838 (1997)
	B20	Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR, "Interaction between hyperthermia in the 5-hydroxytryptaminergic response to a single methamphetamine administration," <i>J Pharmacol Exp Ther</i> , 283:281-285 (1997)
	B21	Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG, "Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice," <i>J Neurosci.</i> , 19:2424-2431 (1999)
	B22	Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF, "Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro," <i>Mol Pharmacol</i> , 14:644-653 (1978)
	B23	Hastings TG, "Enzymatic oxidation of dopamine: the role of prostaglandin H synthase," <i>J Neurochem</i> , 64:919-924 (1995)
	B24	Hogan KA, Staal RG, Sonsalla PK, "Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations," <i>J Neurochem</i> , 74:2217-2220 (2000)
	B25	Hotchkiss AJ, Morgan ME and Gibb JW, "The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tryosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities," <i>Life Sci</i> , 25:1373-1378 (1979)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/528,684
		Filing Date	May 9, 2005
		First Named Inventor	Annette E. Fleckenstein
		Group Art Unit	1614
		Examiner Name	Weddington, K.E.
B26		Insel TR, Battaglia G, Johannessen JN, Marra S and De Souza EB, "3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys," <i>J Pharmacol Exp Ther</i> , 249:713-720 (1989)	
B27		Iwata, S., Hewlett, G.H., Ferrell, S.T., Czernik, A.J., Meiri, K.F., Gnegy, M.E., "Increased in vivo phosphorylation state of neuromodulin and synapsin I in striatum from rats treated with repeated amphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 278:1428-1434 (1996)	
B28		Iwata, S., Hewlett, G.H., Gnegy, M.E., "Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes," <i>Synapse</i> , 26:281-291 (1997)	
B29		Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D, "Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine," <i>Eur. J. Pharmacol.</i> , 373:187-193 (1999)	
B30		Johnston LD, O'Malley PM and Bachman JG, "Ecstasy' use rises sharply among teens in 2000; use of many other drugs steady, but significant declines are reported for some," <i>University of Michigan News and Information Services</i> , Ann Arbor, MI, [On-line], Available: www.monitoringthefuture.org ; accessed 06/08/01, (2000)	
B31		Johnson M, Letter AA, Merchant K, Hanson GR and Gibb JW, "Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat," <i>J Pharmacol Exp Ther</i> , 244:977-982 (1988)	
B32		Kadota K and Kadota T, "Isolation of coated vesicles, plain synaptic vesicles, and flocculent material from a crude synaptosome fraction of guinea pig whole brain," <i>J Cell Biol</i> , 58:135-151 (1973)	
B33		Koda LY and Gibb JW, "Adrenal and striatal tyrosine hydroxylase activity after methamphetamine," <i>J Pharmacol Exp Ther</i> , 185:42-48 (1973)	
B34		Kokoshka JM, Vaughan RA, Hanson GR and Fleckenstein AE, "Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters," <i>Eur J Pharmacol</i> , 361:269-275 (1998)	
B35		LaVoie MJ and Hastings TG, "Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. <i>J. Neurosci</i> , 19(4):1484-1491 (1999)	
B36		LaVoie, M.J., Hastings, T.G., "Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss," <i>J. Neurochem.</i> , 73:2546-2554 (1999)	
B37		Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, "Protein measurement with the folin phenol reagent," <i>J Biol Chem</i> , 193:265-275 (1951)	
B38		Maker HS, Weiss C, Silides DJ, Cohen G, "Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates," <i>J Neurochem</i> , 36:589-593 (1981)	
B39		Metzger RR, Hanson GR, Gibb JW and Fleckenstein AE, "3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function," <i>Eur J Pharmacol</i> , 349:205-210 (1998)	

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/528,684
		Filing Date	May 9, 2005
		First Named Inventor	Annette E. Fleckenstein
		Group Art Unit	1614
		Examiner Name	Weddington, K.E.

	B40	Morgan ME and Gibb JW, "Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei," <i>Neuropharmacology</i> , 19:989-995 (1980)
	B41	Nirenberg MJ, Chan J, Liu Y, Edwards RG and Pickel VM, "Vesicular Monoamine Transporter-2: immunogold localization in striatal axons and terminals," <i>Synapse</i> , 26:194-196 (1997)
	B42	Pan D, Gatley SJ, Dewey SL, Chen R, Alexoff DA, Ding Y, Fowler JS, "Binding of bromine-substituted analogs of methylphenidate to monoamine transporters," <i>Eur. J. Pharmacol.</i> , 264:177-182 (1994)
	B43	Pincus HA, Wise T, First MB, "Diagnostic and Statistical Manual of Mental Disorders," <i>Primary Care Version, Fourth edition</i> , Washington, DC, American Psychiatric Association, 182-184 (1995)
	B44	Schmidt CJ, Gibb JW, "Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid," <i>Eur. J. Pharmacol.</i> , 109:73-80 (1985a)
	B45	Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW, "Role of dopamine in the neurotoxic effects of methamphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 233:539-544 (1985b)
	B46	Seiden LS, Fischman MW and Schuster CR, "Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys," <i>Drug Alcohol Depend.</i> , 1:215-219 (1976)
	B47	Stoof JC, Keababian JW, "Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum," <i>Nature</i> , 294:366-368 (1981)
	B48	Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A, "Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport," <i>J Neurosci</i> , 15:4102-4108 (1995)
	B49	Teng L, Crooks PA, Dwoskin LP, "Lobeline displaces [³ H]dihydrotetrabenazine binding and releases [³ H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine," <i>J. Neurochem.</i> , 71:258-265 (1998)
	B50	Vaccari A, Saba P, "The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins," <i>Eur. J. Pharmacol.</i> , 292:309-314 (1995)
	B51	Vallar L, Meldolesi J, "Mechanisms of signal transduction at the dopamine D2 receptor," <i>Trends Pharmacol. Sci.</i> , 10:74-77 (1989)
	B52	Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA, "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [¹¹ C]WIN-35,428 positron emission tomography studies and direct in vitro determinations," <i>J Neurosci</i> , 18:419-427 (1998)
	B53	Wagner GC, Lucot JB, Schuster CR, Seiden LS, "Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes," <i>Brain Res</i> , 270:285-288 (1983)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)			Complete if Known	
			Application Number	10/528,684
			Filing Date	May 9, 2005
			First Named Inventor	Annette E. Fleckenstein
			Group Art Unit	1614
			Examiner Name	Weddington, K.E.
	B54	Wilson, J.M., Kalasinsky, K.S., Levey, A.I., Bergeron, C., Reiber, G., Anthony, R.M., Schmunk, G.A., Shannak, K., Haycock, J.W., Kish, S.J., "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users," <i>Nat. Med.</i> , 2:699-703 (1996a)		
	B55	Wilson, J.M., Levey, A.I., Bergeron, C., Kalasinsky, K., Ang, L., Peretti, F., Adams, V.I., Smialek, J., Anderson, W.R., Shannak, K., Deck, J., Niznik, H.B., Kish, S.J., "Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users," <i>Ann Neurol</i> , 40:428-439 (1996b)		
	B56	Wilson, J.M., Kish, S.J., "The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat," <i>J. Neurosci.</i> , 16:3507-3510 (1996)		
	B57	Zuddas A, Ancilletta B, Muglia P, Cianchetti C, "Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset," <i>Eur. J. Paediatr. Neurol.</i> , 4:53-62 (2000)		

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	